CD19 Research Products

CD19 Products

CD19, a cell surface protein specific to B cells, has emerged as an effective immunotherapy target to treat B cell malignancies and autoimmune diseases.

By leveraging monoclonal antibodies, chimeric antigen receptor (CAR) T cells and NK cells, or bispecific T cell/NK cell engagers (BiTEs/BiKEs), CD19-directed immunotherapies aim to selectively eliminate CD19-expressing cells. In cancer, these therapies have shown remarkable efficacy in treating B cell malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), leading to durable remissions in many patients. Furthermore, in autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, targeting CD19 has demonstrated potential in rebalancing aberrant immune responses. This targeted approach offers a promising avenue for precision medicine, with ongoing research focused on refining therapeutic strategies and expanding the scope of CD19-directed immunotherapy.

CD19 Product Interaction Diagram

A Suite of Critical Tools for CD19 Immunotherapy Research

Cell Lines & Primary Cells

CD19 Cell Lines and Primary Cells

Recombinant Proteins

CD19 Recombinant Proteins
  • Recombinant CD19 with functionalized IgG Fc and AviTag™
  • PE and Biotin conjugates available
  • View Products

Antibodies & BiTEs

CD19 Antibodies
  • Biotin, FITC, and PE antibody conjugates available
  • Bispecific and tri-specific molecules
  • View Products

High-Titer Lentiviruses and AAVs

CD19 Viruses
  • For expression of anti-CD19 CARs on effectors or CD19 on target cells of interest
  • Second and third generation CARs, including a tri-specific construct
  • View Lentiviruses
  • View AAVs

Cellular Kits

CD19 Cellular Kits

Product Results

Reset Filters
Catalog #